Long-Term Data Support Frontline Avelumab and Axitinib for Advanced RCC
Combination avelumab and axitinib has shown long-term activity in previously untreated patients with advanced renal cell carcinoma.
Combination avelumab and axitinib has shown long-term activity in previously untreated patients with advanced renal cell carcinoma.
After physicians voiced concerns about an active surveillance recommendation, the NCCN panel revised the guidelines.